Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
DIVIS LABORATORIES | SUN PHARMA | DIVIS LABORATORIES/ SUN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 58.8 | 133.5 | 44.0% | View Chart |
P/BV | x | 13.5 | 3.1 | 442.8% | View Chart |
Dividend Yield | % | 0.5 | 0.7 | 64.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DIVIS LABORATORIES Mar-19 |
SUN PHARMA Mar-20 |
DIVIS LABORATORIES/ SUN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,639 | 484 | 338.6% | |
Low | Rs | 1,115 | 315 | 353.7% | |
Sales per share (Unadj.) | Rs | 186.3 | 136.9 | 136.1% | |
Earnings per share (Unadj.) | Rs | 51.0 | 17.5 | 292.0% | |
Cash flow per share (Unadj.) | Rs | 57.3 | 26.0 | 220.4% | |
Dividends per share (Unadj.) | Rs | 16.00 | 4.00 | 400.0% | |
Dividend yield (eoy) | % | 1.2 | 1.0 | 116.1% | |
Book value per share (Unadj.) | Rs | 261.8 | 188.7 | 138.8% | |
Shares outstanding (eoy) | m | 265.47 | 2,399.26 | 11.1% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 7.4 | 2.9 | 253.1% | |
Avg P/E ratio | x | 27.0 | 22.9 | 118.0% | |
P/CF ratio (eoy) | x | 24.0 | 15.4 | 156.3% | |
Price / Book Value ratio | x | 5.3 | 2.1 | 248.3% | |
Dividend payout | % | 31.4 | 22.9 | 137.0% | |
Avg Mkt Cap | Rs m | 365,592 | 958,864 | 38.1% | |
No. of employees | `000 | 11.8 | 17.8 | 66.7% | |
Total wages/salary | Rs m | 5,423 | 63,624 | 8.5% | |
Avg. sales/employee | Rs Th | 4,175.1 | 18,490.6 | 22.6% | |
Avg. wages/employee | Rs Th | 457.7 | 3,582.6 | 12.8% | |
Avg. net profit/employee | Rs Th | 1,141.8 | 2,357.6 | 48.4% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 49,463 | 328,375 | 15.1% | |
Other income | Rs m | 1,556 | 6,360 | 24.5% | |
Total revenues | Rs m | 51,019 | 334,735 | 15.2% | |
Gross profit | Rs m | 18,718 | 69,898 | 26.8% | |
Depreciation | Rs m | 1,689 | 20,528 | 8.2% | |
Interest | Rs m | 35 | 3,027 | 1.2% | |
Profit before tax | Rs m | 18,551 | 52,702 | 35.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -2,606 | 0.0% | |
Tax | Rs m | 5,023 | 8,228 | 61.1% | |
Profit after tax | Rs m | 13,527 | 41,868 | 32.3% | |
Gross profit margin | % | 37.8 | 21.3 | 177.8% | |
Effective tax rate | % | 27.1 | 15.6 | 173.4% | |
Net profit margin | % | 27.3 | 12.8 | 214.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 46,501 | 316,542 | 14.7% | |
Current liabilities | Rs m | 8,468 | 157,064 | 5.4% | |
Net working cap to sales | % | 76.9 | 48.6 | 158.3% | |
Current ratio | x | 5.5 | 2.0 | 272.5% | |
Inventory Days | Days | 131 | 88 | 149.4% | |
Debtors Days | Days | 86 | 105 | 82.0% | |
Net fixed assets | Rs m | 25,797 | 243,102 | 10.6% | |
Share capital | Rs m | 531 | 2,399 | 22.1% | |
"Free" reserves | Rs m | 68,962 | 450,245 | 15.3% | |
Net worth | Rs m | 69,493 | 452,645 | 15.4% | |
Long term debt | Rs m | 0 | 20,289 | 0.0% | |
Total assets | Rs m | 80,383 | 682,525 | 11.8% | |
Interest coverage | x | 531.0 | 18.4 | 2,884.6% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.5 | 127.9% | |
Return on assets | % | 16.9 | 6.6 | 256.5% | |
Return on equity | % | 19.5 | 9.2 | 210.4% | |
Return on capital | % | 26.7 | 11.2 | 238.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 24.6 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 12,187 | NA | - | |
Fx inflow | Rs m | 41,238 | 74,219 | 55.6% | |
Fx outflow | Rs m | 12,405 | 27,964 | 44.4% | |
Net fx | Rs m | 28,833 | 46,255 | 62.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 9,543 | 65,548 | 14.6% | |
From Investments | Rs m | -6,854 | -25,888 | 26.5% | |
From Financial Activity | Rs m | -2,459 | -57,151 | 4.3% | |
Net Cashflow | Rs m | 230 | -13,857 | -1.7% |
Indian Promoters | % | 52.0 | 63.7 | 81.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 11.8 | 5.1 | 230.0% | |
FIIs | % | 19.0 | 23.0 | 82.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.2 | 8.3 | 207.2% | |
Shareholders | 31,796 | 133,026 | 23.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.5 | - |
Compare DIVIS LABORATORIES With: SHASUN PHARMA WYETH GSK PHARMA ALEMBIC DR. REDDYS LAB
Compare DIVIS LABORATORIES With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More